Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Beyond Air, Inc. secures up to $30.1 million in a private placement offering, led by institutional healthcare investors, to support the commercial launch of its second-generation LungFit PH.
PUBLIC · XAIRJul 30, 2026•11 days ago
Amount Raised
$30.1 Million
Round Type
Post-IPO Equity
Garden CityBiotechnologyHealthcareHealth Care
Investors
Dan MoorheadRobert GoodmanInstitutional Healthcare Investors
Description
Beyond Air, Inc. has announced a securities purchase agreement for up to $30.1 million through a private placement offering. The financing, which provides the company with crucial capital, is led by institutional healthcare investors and includes participation from its directors and executive officers. This funding will aid in the planned commercial launch of the LungFit PH, subject to regulatory approval
Company Information
Company
Beyond Air
Location
Garden City, New York, United States
About
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM).
Garden CityBiotechnologyHealthcareHealth Care